- Home
- MNY vs SPRO Comparison
MNY vs SPRO Comparison
Compare MNY & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- SPRO
- Stock Information
- Founded
- MNY 2014
- SPRO 2013
- Country
- MNY Singapore
- SPRO United States
- Employees
- MNY N/A
- SPRO 32
- Industry
- MNY
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- MNY
- SPRO Health Care
- Exchange
- MNY Nasdaq
- SPRO Nasdaq
- Market Cap
- MNY 30.4M
- SPRO 33.0M
- IPO Year
- MNY N/A
- SPRO 2017
- Fundamental
- Price
- MNY $0.79
- SPRO $0.66
- Analyst Decision
- MNY
- SPRO Buy
- Analyst Count
- MNY 0
- SPRO 4
- Target Price
- MNY N/A
- SPRO $5.00
- AVG Volume (30 Days)
- MNY 28.1K
- SPRO 111.2K
- Earning Date
- MNY 06-23-2025
- SPRO 05-13-2025
- Dividend Yield
- MNY N/A
- SPRO N/A
- EPS Growth
- MNY N/A
- SPRO N/A
- EPS
- MNY N/A
- SPRO N/A
- Revenue
- MNY $79,511,000.00
- SPRO $47,977,000.00
- Revenue This Year
- MNY $31.98
- SPRO N/A
- Revenue Next Year
- MNY $10.97
- SPRO N/A
- P/E Ratio
- MNY N/A
- SPRO N/A
- Revenue Growth
- MNY N/A
- SPRO N/A
- 52 Week Low
- MNY $0.55
- SPRO $0.51
- 52 Week High
- MNY $2.75
- SPRO $1.72
- Technical
- Relative Strength Index (RSI)
- MNY 52.46
- SPRO 53.47
- Support Level
- MNY $0.70
- SPRO $0.57
- Resistance Level
- MNY $0.79
- SPRO $0.70
- Average True Range (ATR)
- MNY 0.05
- SPRO 0.04
- MACD
- MNY 0.00
- SPRO 0.01
- Stochastic Oscillator
- MNY 59.50
- SPRO 67.04
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.